CD8 + PD-1 + to CD4 + PD-1 + ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers.
Boris DuchemannMarie NaigeonEdouard AuclinRoberto FerraraLydie CassardJean-Mehdi JouniauxLisa BoselliJonathan GrivelAude DesnoyerFrançois-Xavier DanlosLaura MezquitaCaroline CaramellaAurélien MarabelleBenjamin BesseNathalie ChaputPublished in: Journal for immunotherapy of cancer (2022)
Elevated PERLS, determined from a blood sample before immunotherapy, was correlated with benefit from PD-(L)1 blockers in aNSCLC.